Cancer/Tumor Profiling Market Trends, Outlook, and Opportunity Analysis, 2018–2026

@

Cancer profiling is a technique used to classify tumors more accurately, which helps in predicting the patient’s clinical outcome. Cancer/Tumor profiling helps in identification of genomic alteration, which aid to select an appropriate therapy for the treatment of cancer. This technique reduces the trial and error process in diagnosis of cancer at various stages and provide more precise and accurate information about clinical outcomes of cancer. Different tests are used in the diagnosis of cancer such as laboratory test (blood and urine), biopsy, imaging test (X-ray, MRI, PET/CT, and ultrasound), nuclear medicine scan, and lumber puncture, which is unable to identify exact cause of cancer in early stages. This can be led to over-treatment of cancer patients.

Get Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/967

According to the World Health Organization (WHO), nearly 1 in 6 deaths occurs due to cancer and around 8.8 million people died from cancer worldwide in 2015. Increasing incidence and prevalence of different cancers among individuals augmented the demand for accurate diagnosis of cause in early stage of cancer.

Emergence of cancer profiling over traditional cancer diagnostic methods is expected to gain growth of the Cancer/Tumor profiling market:

St. Jude Medical Center's Crosson Cancer Institute has joined Caris’ Precision Oncology Alliance (POA) as its 17th member in 2017. POA is established by Caris Life Sciences to promote the appropriate use of molecular tool in diagnosis and treatment of cancer. The St. Jude Medical Center's Crosson Cancer Institute will help Caris Life Sciences to develop standard and best practices to make cancer treatment more effective and precise by advancing the use of tumor profiling.

EpiVax Inc. launched EpiVax Oncology Inc., which is an approach for precision cancer immunotherapy in 2017. EpiVax used molecular profiling through Next-Generation Sequencing (NGS) to produce therapeutic vaccines for cancer.

Personal Genome Diagnostics Inc. launched CancerSELECT 125 test for pan-cancer tumor profiling in 2016. CancerSELECT 125 identify tumor specific functional sequence mutation in multiple cancer types with high accuracy.

Some of the major key players operating in the global cancer profiling market include Proteome Sciences PLC, Life Technologies Corporation, Illumina, Inc., BioTheranostics, RiboMed Biotechnologies Inc., NeoGenomics Laboratories, Oxford Gene Technology Ltd., Genomic Health Inc., Agendia, and Oncopath Laboratories.

Cancer Profiling Market Taxonomy:

By Technology

Microarray, Next-Generation Sequencing (NGS), Quantitative Polymerase Chain Reaction (QPCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Fluorescence In Situ Hybridization (FISH), Chromogenic In Situ Hybridization (CISH)

By Technique

Genomics, Proteomics, Epigenetics, Metabolomics

By Application

Diagnostics, Personalized Medicine, Biomarker Discovery, Prognostics, Others (Research Applications)

Ask For Discount Before Purchasing This Business Report @ https://www.coherentmarketinsights.com/insight/request-discount/967

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Healthcare related news and fitness trends